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PILOT STUDY: PROGNOSTIC BIOMARKERS FOR INTERSTITIAL LUNG 
DISEASE IN SYSTEMIC SCLEROSIS 
JULIO C. MANTERO 
ABSTRACT 
 Interstitial lung disease is one of the main causes of mortality in Systemic 
Sclerosis. The course of the disease is clinically variable where patients can suffer from a 
range of stable disease to rapid progressive clinical deterioration. Therefore, it is 
important to identify biomarkers that can predict the clinical course of patients in order to 
provide early treatment. We evaluated 1129 proteins utilizing novel high-throughput 
SOMAlogic proteomic technology from the serum of 13 lSSc, 13 progressive ILD and 11 
stable ILD patients. Calpain-1 was significantly elevated in progressive ILD patients 
(median 15129 RFU, 11091-24561) compared to lSSc patients (12759, 9904-15498, 
p=0.0015) and stable ILD patients (11876, 10271-14249, p=0.0005). Coagulation Factor 
V was significantly lower in the progressive ILD patients (7161 RFU, 2140-8296) 
compared to lSSc patients (10311 RFU, 6396-12260, p=0.001) and stable ILD patients 
(9646 RFU, 6510-11941, p=0.0016). The combination of Coagulation Factor V and 
Calpain-1 produced an area under the curve of 0.97 (95% CI, 0.921-0.99), sensitivity of 
99% and specificity of 91% for the identification of progressive ILD. We have identified 
a combination of proteins that show potential to be prognostic biomarkers for ILD in SSc.  
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INTRODUCTION 
Systemic Sclerosis 
 
 Systemic sclerosis (SSc) or scleroderma is a rare, autoimmune, multisystem 
connective tissue disorder characterized by vascular damage, autoimmunity and fibrosis 
of the skin and other internal organs.1–3 The incidence of SSc in the United States is 
estimated to be about 20 cases per 1 million adults, while its prevalence is estimated to be 
about 276 cases per million adults.4 The disease predominantly affects women, with an 
approximate 5:1 ratio of women to men diagnosed.4 The disease seems to be most 
prevalent amongst middle-aged women (35-50 years old) but it can affect women of any 
age as well as men and children.4 The median time of survival of patients with the disease 
is of approximately 11 years after diagnosis.4 The pathogenesis of SSc is not well 
understood. However, it is known that there is a relationship between inflammatory, 
vascular, and fibroblast dysfunction. The clinical manifestations of SSc are varied which 
complicates early and accurate diagnosis of potentially progressive patients.  
 The disease is usually classified into two major clinical subgroups based on the 
extent of skin involvement; limited cutaneous systemic sclerosis (lcSSc) and diffuse 
cutaneous systemic sclerosis (dcSSc).5,6 Patients classified with dcSSc have more 
widespread skin fibrosis involving the trunk and proximal extremities of the body, while 
patients with lcSSc have less extensive skin involvement usually limited to the distal 
extremities including hands, feet, forearms and face.6 To evaluate the extent of the skin 
involvement, physicians utilize the Modified Rodnan Skin Score (MRSS). The score is 
	  2 
obtained during an initial physical examination where the physician manually palpates 17 
areas of the body: fingers, hands, forearms, arms, feet, legs, thighs (in pairs) and face and 
gives each site a score (0-3). The total skin score is the sum of the individual sites, with 
MRSS ranging from zero to fifty-one. Higher MRSS describes more extensive disease. 
 
Interstitial Lung Disease 
 At present, pulmonary disease is the main cause of morbidity and mortality in 
patients with interstitial lung disease (ILD) leading to pulmonary fibrosis (PF), and 
vascular obliteration leading to pulmonary arterial hypertension (PAH).1,7 Together 
pulmonary manifestations account for 60% of SSc related deaths .1,8 The prevalence of 
ILD in SSc patients ranges from 75% to 90%. Amongst the SSc subgroups, ILD seems to 
be more prevalent in patients with dcSSc, while PAH appears to be more common in 
patients with lcSSc .1 The development of ILD often manifests during the first 3 years of 
the disease, however some studies have suggested that it can manifest even 7 years from 
the onset of SSc.9 SSc patients with ILD tend to have a higher mortality than patients 
without organ involvement. Patients with lung involvement have a nine-year survival of 
30% while patients without lung involvement have a nine-year survival of 72%.10  
The presence of antinuclear antibodies (ANA’s) is common in SSc patients; present in 
nearly 90% of patients. In the context of ILD, anti-Scl-70 (anti-topoisomerase I) 
antibodies are associated with a higher prevalence of pulmonary fibrosis and are found in 
approximately 40% of patients with dcSSc and in less than 10% of patients with 
lcSSc.11,12 On the other hand, anticentromere antibodies are less frequently found in 
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patients with lung disease and are associated with a lower prevalence of pulmonary 
fibrosis.12 
 In the clinical setting patients suffering from ILD may complain of shortness of 
breath, dyspnea, dry cough, atypical chest pain and general weakness.1,7 High resolution 
computed tomography (HRCT) is commonly utilized to identify interstitial abnormalities 
in the lungs of SSc patients, and is the standard tool for diagnosis of ILD in SSc. Septal 
and subpleural line opacities, ground glass opacities and subpleural cysts are early signs 
of ILD. Progression of ILD is characterized by the formation of honeycombing and 
bronchiectasis.13,14 Formation of fibrotic tissue in the lungs results in restrictive changes 
in the lung function of patients.13,14 Pulmonary function tests (PFT’s) are performed to 
identify and monitor the extent and progression of these changes in the lungs. Force vital 
capacity (FVC), defined as the amount of air that can be forcibly exhaled from the lungs 
after taking the deepest breath possible, is the most commonly monitored value by 
physicians to determine the severity and progression of the disease. At baseline, the 
severity of ILD can be classified on a scale where predicted FVC values of >80% are 
considered normal, 70-79 % (mild), 50-69% (moderate) and 50% (severe).7 Reductions 
of  >10% of FVC from baseline over a period of 3-12 months indicates disease 
progression.7 
Treatment Options 
 Current treatments for ILD in SSc include the use of corticosteroids, 
immunosuppressant agents, autologous hematopoietic stem cell transplantation and lung 
transplantation. Corticosteroids such as Prednisone are commonly utilized in SSc but 
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their use in high doses have been associated with the onset of scleroderma renal crisis 
(SRC) and are mostly utilized in lower doses in combination with Cyclophosphamide. 
Cyclophosphamide is the most utilized immunosuppressant for the treatment of ILD in 
SSc. The effectiveness of Cyclophosphamide in SSc has been extensively studied but 
variable results regarding its effectiveness, small improvements in pulmonary function 
alongside the numerous side effects associated with the drug has emphasized the need for 
alternative less toxic therapies .15,16 
  Mycophenolate mofetil (MMF) is another immunosuppressive agent that has 
become an alternate option for patients that are not able to tolerate Cyclophosphamide. In 
retrospective and prospective studies its use has been associated with improvement or 
stabilization of lung function however such studies have involved been small samples of 
subjects, thus requiring larger controlled studies will be needed to truly assess its 
effectiveness.15 Hematopoietic stem cell transplantation (HSCT) is another approach that 
attempts to downregulate the aberrant immune reaction that appears to drive the disease. 
Various clinical trials have demonstrated that treatment of severe SSc patients with 
HSCT can improve MRSS and FVC over baseline measurements.17 The caveat with this 
treatment is that it is associated with a high risk of mortality and toxicity.18  
 Thus, treatment options for SSc-ILD come with significant treatment-associated 
morbidity and mortality.17 Currently the ability to predict the progression of ILD in SSc 
patients at time of diagnosis is extremely challenging because the disease is clinically 
variable and in some cases highly progressive, while in others it stabilizes without the 
need of treatment.19 Therefore, identifying the patient population at higher risk of disease 
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progression is extremely important. The identification of one or multiple biomarkers that 
distinguish patients likely to have progressive ILD would allow physicians to identify 
patients who need to be treated with these aggressive treatments and spare those who are 
at a lower risk for clinical progression. Currently there are no clinically validated 
prognostic biomarkers for ILD that would enabled physicians predict the rate of 
progression of ILD over time, indicating the importance of discovering and validating 
new biomarkers to address this unmet clinical need.20,21 
Biomarkers 
 Biomarkers are objective outcome measures that are used to measure a biological 
process or assess the response to a therapeutic intervention.  They provide valuable 
information for more efficient performance of clinical trials while simultaneously 
creating a bridge to understanding disease pathogenesis.22 Biomarkers already permeate 
clinical care as commonly used laboratory tests. Some examples are laboratory tests to 
assess TSH levels for thyroid disease, PSA for prostate cancer or CK levels to assess the 
occurrence of muscle injury and myocardial infarction.22 There are different types of 
biomarkers that can be applied for different purposes including diagnostic, predictive, 
prognostic and pharmacodynamics biomarkers. Diagnostic biomarkers are utilized to 
identify patients who suffer from a particular disease, condition or complication. 
Predictive biomarkers provide information about the likelihood of a patient responding to 
a specific treatment. Pharmacodynamic biomarkers are utilized to determine the 
effectiveness of a therapeutic intervention and are often utilized as endpoints in clinical 
trials. Prognostic biomarkers indicate the future clinical course of the patient in the 
	  6 
context of a particular clinical outcome without regard to treatment.23 Identifying 
prognostic biomarkers for ILD in SSc would directly impact the treatment plan of 
patients that would suffer from the progressive disease by identifying patients at risk 
earlier and provide early therapy.24  
 Currently, the only way to identify subjects whose ILD will progress is by 
performing multiple PFT’s and assessing whether there are any changes in FVC. This 
poses a problem because while patients are waiting to get new PFT’s they are not being 
treated and their lungs are potentially suffering irreversible damage.  
In addition, clinical trials could also benefit from prognostic biomarkers. Trial 
populations could be enriched with subjects who suffer from progressive disease making 
trials designed to test progression of the disease more robust.25 Therefore, prognostic 
biomarkers could help identify those subjects who will develop progressive ILD, reduce 
the number of subjects in clinical trials, and avoid exposing subjects with stable disease 
to the risks potentially associated with the investigational therapy. 
 Other researchers have investigated several potential biomarkers for progressive 
disease. High levels of CXCL-4 in the plasma have been shown to correlate with the 
presence of lung fibrosis.26 However, this study included a wide spectrum of SSc patients 
and did not specifically look at whether CXCL-4 levels were different in patients with 
progressive ILD compared to stable ILD patients and the results have yet to be 
independently validated. Previous studies have identified several serum proteins like 
Krebs von Lungen-6 (KL-6), surfactant protein-D (SP-D) and CCL18 as candidate 
prognostic biomarkers.19,22,24,27–29,30 An increase of these markers has been seen in 
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patients with ILD, however their validation as prognostic biomarkers has not been 
possible because of inconsistent and variable measurements when correlating with 
FVC.19 
 Other groups have studied the broncheoalveolar lavage fluid (BALF) of patients 
to understand more about the pathogenesis of ILD and to find biomarkers.31,32 One of the 
studies identified high concentrations of CXCL5, CXCL8 and S100A8/A9 in the BALF 
of patients that were statistically significant when compared to healthy controls. These 
analytes also correlated with findings on HRCT and may serve as markers for the 
presence and extent of lung fibrosis31. High levels of cytokines in BALF were observed 
in another study where SSc patients with ILD had higher concentrations of IL-4, IL-6, IL-
8 and CCL2 compared to controls and correlated negatively with FVC.32 This approach 
offers the opportunity of studying the lung tissues more closely, however obtaining 
BALF is more invasive and thus a more difficult source to obtain multiple measurements. 
Thus, one could question their practicality in a clinical setting.19  
 In this study we utilize a novel proteomic technology called SOMAscan to assess 
and identify, quantitative protein differences between subjects with stable ILD and 
progressive ILD in order to identify potential prognostic biomarkers. This is a high 
throughput technology that measures a higher number of proteins in serum than 
commonly used mass-spectrometry. Mass-spectrometry is difficult to use on serum 
samples due to the loss of sensitivity due to the high abundance from several very 
common serum proteins such as albumin, making it hard to identify biomarkers.33 The 
technology is composed of a capture array called SOMAscan using a Slow Off-rate 
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Modified Aptamer (SOMAmer) that transforms protein signal to nucleotide signal that 
allows quantification of 1,129 proteins by relative florescence. This technology has been 
utilized widely utilized in other studies with the purpose of identifying biomarkers in 
other disease and has provided positive results. Studies include the identification of 
biomarkers in inflammatory arthritis and identification of plasma protein biomarkers 
associated with cognitive decline in Alzheimer’s disease patients.34,35  
 Also, looking at proteins in the serum is a less invasive and more practical way of 
biomarker identification since serum is easily obtainable. 
Objective/Aims 
 The aim of this study is to discover and develop one or multiple prognostic 
biomarkers that would allow identifying subjects that will develop progressive ILD. 
Previously several biomarkers for ILD have been studied, however results have not been 
validated successfully. ILD is one of the main causes of mortality in SSc thus discovering 
new and better biomarkers is of importance. This study will use a dataset of 1,129 
analytes obtained from a total of 40 samples that were sent for proteomic profiling to 
SOMAlogic. This study is unique because it is the first study to utilize this technology to 
identify prognostic biomarkers for ILD in SSc. The obtained dataset will be analyzed to 
identify differences in protein expression between progressive and stable ILD subjects. A 
shortlist of analytes will be developed, by calculating false discovery rates, to identify 
those that might serve as potential biomarkers. Then by using linear regression models 
we will attempt to identify one or a combination of analytes that will identify subjects 
that will develop progressive ILD. 
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METHODS 
 
Ethics Statement 	   This study was conducted under a protocol approved by the Institutional Review 
Board of Boston University Medical Center. All patients signed informed written consent 
forms approved by the Boston University Medical Center Institutional Review Board.  
Study Subjects 	   All the samples analyzed in this study consisted of patients enrolled the 
Scleroderma Clinical Repository (SCaR) located at Boston University Medical Center. 
The repository contains a population of approximately 500 subjects that have been 
recruited from the Boston Medical Center Rheumatology and Pulmonary clinics.  
All study subjects have met the criteria for limited cutaneous systemic sclerosis (lSSc) as 
defined by the American College of Rheumatology (ACR). Subjects with lSSc were 
stratified into three groups those with no ILD (16 subjects), those with progressive ILD 
(13 subjects) and those with stable ILD (11 subjects). LSSc subjects showing evidence of 
ILD and confirmed by HRCT where considered to have ILD (24 subjects).  	   ILD subjects were further stratified in two groups those with progressive disease 
and those with stable disease. Subjects were determined to be progressive or stable based 
on the total trend in FVC measurements from serial PFT’s that were collected 24 months 
before and after sample collection, which were obtained through the available database 
data and medical records review. Each of the subject’s FVC measurements was graphed 
to determine which subjects had progressive disease versus those who had stable disease. 
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Subjects with PFT’s that showed an overall trend of decline (>5% decrease) of FVC over 
a 48-month period (Figure 1A) were classified as progressive (13 subjects). Subjects 
whose PFT’s showed minimal changes, defined as less than 5% decrease, or increasing 
FVC over 48 months (Figure 1B) were classified as stable (11 subjects).  	   Demographic characteristics and clinical manifestations were assessed for the 
subjects including history (age and sex,), and medical records (disease duration, ILD 
duration, HRCT, PFT’s, concomitant medications,). LSSc disease duration was measured 
from the date the subject was first diagnosed with lSSc by a rheumatologist. ILD duration 
was measured from the date of diagnosis and confirmed by HRCT. 
  
Figure 1A. FVC trajectories for progressive ILD subjects 
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Figure 1B. FVC trajectories for stable ILD subjects 
Sample Collection 	   Biomarkers were assayed from stored serum samples that were collected from 
patients as part of the SCaR repository at Boston University School of Medicine. Serum 
was collected in standard Serum Separator Tubes (BD Vacutainer) in accordance with 
manufacturer’s instructions and mixed and centrifuged at 1,200g at room temperature for 
15 minutes. Serum was then aliquoted into collection tubes in volumes of 250ul, 500ul 
and 1000ul and frozen at -80 Celsius immediately after collection.  
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Biomarker measurement 	   Proteins were measured using a the high throughput technology called 
‘SOMAscan’ (SomaLogic, Inc, Boulder, Colorado). This approach uses chemically 
modified nucleotides to transform a protein signal to a nucleotide signal that can be 
quantified using relative florescence on microarrays. This assay simultaneously measured 
the level of 1,129 human proteins in a single sample.  
Statistical Analysis 	   Continuous data is presented as the median and range and categorical data is 
presented as percentages. Proteomic data was analyzed utilizing R-(version 0.98.1102)  
and Prism (graphpad version 6.0g). Difference in protein expression between progressive 
and stable ILD was calculated by Wilcoxon rank sum test.  Difference in protein 
expression between ILD vs no ILD was also calculated by Wilcoxon rank sum test. 
Resulting p-values from the two Wilcoxon rank sum tests  were combined by Fischers 
test. Then, to reduce Type-I error, false discovery rates (FDRs) was implemented to 
adjust p-values for multiple comparisons and adjusted p-values of less than 0.1 were 
considered to indicate potential statistical significance. Fifty analytes had adjusted p-
values less than 0.1 and were used for unsupervised hierarchical clustering to assess 
whether the progressive and stable groups independently separated based solely on 
association between analytes within the phenotypic groups. Then, seven analytes were 
selected based on their association with other analytes, each of the seven analytes that 
were selected was in a different cluster in order to avoid selecting overly similar analytes. 
The Kruskal-Wallis test was used to assess for differences across the three groups and 
	  13 
correcting with Dunn’s multiple comparison post-test was employed to analyze 
differences in the mean expression between lSSc with no ILD, stable and progressive 
groups for these seven analytes. Statistical significance was considered as p-values of 
<0.05. Disease status (dependent variable) was dichotomized in order to build logistic 
regression models to determine if selected analytes (independent variable) predict disease 
progression versus stable. Linear regression is a common statistical method utilized to 
test whether one or more independent variables determine an outcome. The utility of the 
biomarkers was assessed by utilizing sensitivity and specificity measurements and the 
area under the receiver operating characteristic (ROC) curve in order to identify specific 
cut-off values for the proteins. 
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RESULTS 
 
 
 Baseline characteristics of the study subjects are shown in Table 1. SSc disease 
duration in the progressive ILD group was found to shorter when compared to lSSc 
(p=0.04) and to the stable group (p=0.02).  The baseline FVC, defined as the closest 
value to sample collection, was found to be significantly lower in both ILD groups 
(progressive (p=0.0001), stable (p=0.0012)) when compared to the no ILD lSSc group. 
ILD disease duration was found to be significantly greater (p=0.0024) in the stable ILD 
group when compared to the progressive ILD group. 
 
Table 1. Study subjects characteristics 
Identification of differentially expressed proteins between progressive ILD and 
stable ILD 
 Based on the 1129 proteins from the SOMAscan assay data from 16 lSSc 
subjects, 11 stable ILD and 13 progressive ILD; we identified 50 proteins that were 
differentially regulated between progressive ILD and stable ILD ( Wilcox rank sum test 
False Discovery Rate (FDR) <0.1) Out of the 50 proteins identified, 25 proteins were 
upregulated (significantly increased) and 25 proteins were downregulated (significantly 
decreased) in the progressive ILD group compared to stable ILD group. The 
LSSc (16) PRO (13) STA (11) LSSc vs PRO LSSc vs STA PRO vs STA
Age (years) Median (range) 56.50 (25-70) 47 (31-59) 59 (29-77) ns ns ns
Percent Female (n) 88% (14) 77% (10) 100% (11)  -  -  -
Percent Male (n) 12% (2) 23% (3)  -  -  -  -
SSc duration (months) Median (range) 84 (7-348) 24 (0-96) 96 (1-216) 0.0349 > 0.9999 0.0151
ILD duration (months) Median (range)  - 12 (0-43) 60 (5-108)  -  - 0.0024
FVC (% predicted) Median (range) 106.9 (91-154) 71 (49-115) 80 (53-93) 0.0001 0.0012 > 0.9999
Immunosuppresors 2 (13) 6 (46) 4 (36)  -  -  -
Corticosteroids 2 (13) 3 (19)  -  -  -  -
Subject Demographics
Sex
Medications (%)
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discriminatory power of these differentially expressed proteins was tested using 
unsupervised hierarchical clustering. As shown in Figure 2, the spectral counts of these 
proteins resulted in near complete separation of the progressive cases from the stable 
cases with only one exception where one stable case was clustered with the progressive 
cases. There was visible overlap between the lSSc cases and the stable cases. Four 
upregulated proteins (Activin-A, PARC, Calpain-1, and TARC) and three downregulated 
(Kallistatin, Adiponectin, and Coagulation Factor V) were selected based on clustering 
analysis and statistical significance. 
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Figure 2 Heatmap. Unsupervised hierarchical clustering was carried out on the basis of 
the expression pattern. The differentially expressed proteins were linked together 
according to their expression (dendogram on the left) LSSc, stable ILD and progressive 
ILD were also clustered (dendogram on top). Protein expression intensities were 
standardized between -3.0 (blue) and 3.0 (red)  
 
 
 
 
t
lSSc/Stable
xt
Progressive
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Serum levels of biomarkers 
 Median values for serum Coagulation Factor V were 10311 RFU (6396 to 12260) 
for lSSc, 7161 RFU (2140 to 8296) for progressive ILD patients and 9646 RFU (6510 to 
11941) for stable ILD patients. Progressive ILD patients demonstrated significant lower 
Coagulation Factor V levels than lSSc patients (p=0.001) and stable ILD patients 
(p=0.0016) (Figure 3A).  
 
Figure 3A. Comparison of Serum Coagulation Factor V in lSSc, stable ILD (STA) and 
progressive ILD (PRO). 
 Median values for serum Calpain-1 were 12759 RFU (9904 to 15498) for LSSc, 
15129 RFU (11091 to 24561) for progressive ILD and 11876 RFU (10271 to14249) for 
stable ILD patients. Progressive ILD patients had higher levels of Calpain-1 than LSSc 
patients (p=0.0015) and stable ILD patients (p=0.0005) (Figure 3B). 
LS
Sc ST
A
PR
O
0
5000
10000
15000
Coagulation Factor V 
R
FU
***
ns
***
	  18 
 
Figure 3B Comparison of Serum Calpain-1 in lSSc, stable ILD (STA) and progressive 
ILD (PRO). 
 Median values for serum PARC in LSSc patients were 4979 RFU (2356 to 
14943), 9140 RFU (4319 to 14476) in progressive ILD patients and 5286 RFU (3345-
8628) for stable ILD patients. Progressive ILD patients had higher levels of PARC than 
LSSc patients (p=0.0056). Serum levels of PARC was not found to be significant 
between Progressive and stable ILD patients (p=0.0938) (Figure 3C). 
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Figure 3C Comparison of Serum PARC in lSSc, stable ILD (STA) and progressive ILD 
(PRO). 
 Results of the comparisons of other evaluated proteins are shown in Table 2  
 
 
Table 2. Comparison of serum biomarkers as measured by Krustal-Wallis Test. Data are 
presented as median (range) 
 Evaluation of the selected biomarkers 
Each of the seven proteins were examined for their individual ability to discriminate 
between subjects with progressive ILD and those with stable ILD.  In analytes where 
subjects with progressive ILD have higher protein levels than those with stable ILD, the 
LS
Sc ST
A
PR
O
0
5000
10000
15000
20000
PARC
R
FU
*
ns
*
Analyte LSSc Progressive Stable LSSc vs PRO LSSc vs STA PRO vs STA
Coagulation Factor V 10311 (6396-12260) 7161 (2140-8296) 9646 (6510-11941) 0.001 > 0.9999 0.0016
Adiponectin 4127 (1276-7859) 1698 (1069-4657) 2489 (1679-8877) 0.0015 0.6934 0.1294
TARC 1329 (823-2828) 2696 (598-6800) 1276 (621-2737) 0.036 > 0.9999 0.0393
PARC 4979 (2356-14943) 9140 (4319-14476) 5286 (3345-8628) 0.0056 > 0.9999 0.0938
Calpain-1 12759 (9904-15498) 15129 (11091-24561) 11876 (10271-14249) 0.0015 > 0.9999 0.0005
Kallistatin 50529 (31165-64497) 40940 (25372-44877) 50827 (38456-58878) 0.001 > 0.9999 0.004
Activin-A 7049 (4010-10893) 11156 (6916-16491) 6961 (4027-11761) 0.0011 > 0.9999 0.0269
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area under the curve (AUC) represents the probability that a randomly selected 
progressive ILD patient will have a higher test result than randomly selected stable ILD 
patients.  95% Confidence intervals for AUC were calculated using n=1000 bootstrap 
replicates. Receiver-operating characteristic (ROC) curves were developed to evaluate 
and compare the prognostic power of our seven selected biomarkers. Positive predictive 
value (PPV) and negative predictive values (NPV) were also calculated. PPV measures 
the proportion of positive test that are true positives and represent the presence of 
progressive ILD whereas the NPV measures the proportion of negative test that are true 
negatives and represent the absence of progressive ILD.  
When progressive ILD patients were compared to patients with stable ILD, a Coagulation 
Factor V cut-off level of 8,424.64 RFU identified the presence of progressive ILD with a 
sensitivity of 99%, specificity of 82%, PPV of 87%, NPV of 99% and area under the 
curve (AUC) of 0.93 (95% CI 0.82-1).  
A Calpain I threshold of 13,717.55 RFU identified the presence of progressive ILD with 
a sensitivity of 92%, specificity of 91%, PPV of 92%, NPV of 90% and AUC of 0.93 
(95% CI 0.82-1).  
Using a PARC threshold of 8,884.0 RFU, sensitivity, specificity, and AUC for 
progressive ILD were 54%, 99% and 0.80 (95% CI 0.62-0.98) respectively.  
Twelve out of the thirteen patients with progressive ILD , had Calpain I serum RFU 
measurements above the threshold. All of the progressive ILD patients had Coagulation 
Factor V measurements under the threshold. Therefore all of the progressive ILD patients 
were within the cut-off levels of Calpain I and Coagulation Factor V. Two stable ILD 
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patients had Coagulation Factor V measurements under the threshold, however these 
patients were also under the Calpain I threshold.  
 ROC measurements of the other evaluated proteins are shown in Table 3. 
Graphical depictions of the ROC curves are shown in Figure 4. A logistic regression 
model was built to observe if the combination of two biomarkers increase the power of 
the prognostic test (Figure 5). The two proteins chosen to build the model were 
Coagulation Factor V and Calpain I they were chosen for combination because out of the 
seven selected proteins they have the highest AUC with an identical 0.93.  Combining 
both measurements resulted in an AUC of 0.97 (95% CI 0.91-1), sensitivity of 99%, 
specificity of 91%, PPV of 93% and NPV of 99% that was superior to the individual 
measurements of the proteins (Table 4).  
 
Table 3. Logistic Regression Model ROC measurements 
Analyte AUC 95% CI Threshold Sensitivity Specificity PPV NPV
Activin-A 0.82 0.65-0.99 7709.95 0.92 0.64 0.75 0.88
Calpain-1 0.93 0.82-1 13717.55 0.92 0.91 0.92 0.90
Coagulation Factor V 0.93 0.82-1 8424.65 1.00 0.82 0.87 1.00
TARC 0.79 0.59-0.98 2040.50 0.77 0.82 0.83 0.75
Kallistatin 0.89 0.73-1 45863.10 1.00 0.82 0.87 1.00
PARC 0.80 0.62-0.98 8884.00 0.54 1.00 1.00 0.65
Adiponectin 0.78 0.58-0.97 1897.85 0.62 0.91 0.89 0.67
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Figure 4. Analytes ROC curves 
 
 
Table 4. Combined Logistic Regression Model ROC measurements 
 
Figure 5. Combined Analytes ROC curve 
 
Analyte combination AUC 95 % CI Sensitivity Specificity PPV NPV
Calpain-1 + Coagulation Factor V 0.972 0.9123-0.99 0.99 0.909 0.93 0.99
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DISCUSSION 
 
 In the clinical setting a prognostic biomarker is one that can separate a diseased 
population into groups of similar prognosis. In SSc, there is an important need for 
identifying prognostic biomarkers for ILD in SSc. The alarming fact that almost 90% of 
subjects with SSc will develop some sort of pulmonary complication including ILD 
highlights this need. Utilizing prognostic biomarkers in the serum of patients provides a 
non-invasive approach to predict the likelihood of ILD progression and allow early 
treatment to those at risk while avoiding unnecessary treatment for those whose disease 
will remain stable without treatment.24 Prognostic biomarkers will also contribute to the 
ability to enrich the population enrolled into clinical trials where at the present it may 
consist of a large number of subjects with stable disease. The enrollment of a large 
amount of subjects with stable ILD can potentially obscure the effects of potentially 
effective therapeutic treatments.  
 In this pilot study the levels of several proteins were found to be different in the 
serum of subjects with progressive ILD compared to stable ILD. This is the first study to 
use Somascan’s high throughput aptamer-based technology to evaluate the proteomic 
profile of systemic sclerosis patients with ILD. This type of technology provides an 
unbiased approach by providing efficient highly multiplexed measurements of thousands 
of proteins from small samples volume.  
 The literature surrounding the mechanistic aspects of several of these proteins 
make them particularly interesting in their potential utility to be prognostic biomarkers. 
Calcium-dependent intracellular cysteine protease (Calpain-1) shown here to be 
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positively associated with progressive ILD (p=0.0005), has been previously associated to 
play a role in other autoimmune diseases such as Rheumatoid Arthritis (RA).36 
Furthermore, a previous study investigated whether Calpetin, a calpain inhibitor, 
prevented pulmonary fibrosis on bleomycin-induced mice. The group found that Calpetin 
prevented bleomycin-induced pulmonary fibrosis and decreased mRNA levels of genes 
associated with pulmonary fibrosis like IL-6 and TGF-B1 in the treated mouse lung 
tissues.36 These results seem to support the role of Calpain-1 in the progression of 
pulmonary fibrosis and could also suggest that it might be a good therapeutic target.  
 Another protein identified as downregulated in subjects with progressive ILD 
(p=0.0016) is Coagulation Factor V, which functions as a cofactor in the coagulation 
system. Recent evidence has demonstrated evidence that procoagulant signaling 
contributes to inflammation and fibrosis.37,38 In addition, the coagulation system interacts 
with the complement system where dysregulation or inhibitory functions in one or both 
systems are associated with clinical manifestations of systemic lupus erythematosus.39 
The combination of Factor V and X results in the production of high quantities of 
thrombin a known mediator of pulmonary fibrosis in SSc-ILD and idiopathic pulmonary 
fibrosis (IPF). These results could suggest and support the belief that the coagulation 
system plays an important role in SSc-ILD and to our knowledge this is the first study to 
find such evidence in SSc patients with progressive ILD.  
 Calpain-1 and Coagulation Factor V were combined utilizing a generalized linear 
model to increase their prognostic power. The combined performance of these 
biomarkers was assessed by the area under the receiver-operator characteristics curve, 
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which is the most utilized measure to test the discriminatory ability of single biomarkers 
for binary disease outcomes. The combination of the markers produced an AUC of 0.97 
(95% CI, 0.91-0.99), and a sensitivity of 99% and a specificity of 91%. Since the sample 
size in this study was small and the stable ILD group only included females, confounders 
and covariates were not included in the combined logistic regression model. 
 In addition to Calpain-1 and Coagulation Factor V we were able to identify other 
proteins that were differentially regulated between progressive ILD and stable ILD 
including Thymus and activation regulated chemokine (TARC) and Pulmonary and 
activation-regulated chemokine (PARC). TARC also known, as CCL17 is a chemokine 
that is usually expressed in the thymus. Chemokines are key factors that regulate the 
recruitment of specific immune cells into inflamed tissue. Previously TARC serum levels 
have been shown to be significantly elevated in patients of rheumatic disease including 
SSc.40 It has also been demonstrated that TARC might play a key role in the development 
of pulmonary fibrosis by recruiting immune cells such as lymphocytes and 
macrophages.41 In line with previous literature this study found that the serum levels of 
TARC in patients with progressive ILD were significantly elevated (p= 0.03) when 
compared to subjects with stable ILD. TARC also showed a good specificity value of 
82% suggesting its ability to correctly identifying subjects that do not have progressive 
ILD. These findings support previous suggestions that TARC may be a good marker for 
progressive ILD.40,41  
 PARC also known as CCL18 is a chemokine that has also been previously 
described as a potential indicator of ILD activity in idiopathic ILD and SSc-ILD.22,28–30 
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Studies have shown higher levels of PARC in the lung tissue and serum when compared 
to controls. In our dataset we were not able to find statistical differences between the 
progressive ILD and stable ILD (p=0.09), however it seems to be trending towards 
statistically significance and a larger sample size might find a more robust difference.  
The small sample size of this study is a limitation, but it provides a starting point in the 
novel identification of potential prognostic biomarkers for ILD and new interest in 
combinations of analytes that have not been studied before. Another limitation is the lack 
of a validation cohort. The previous observation with TARC allows the current dataset to 
validate this analyte, but for other analytes we hope to identify another patient population 
as a validation cohort for the future. This cohort only included lSSc subjects who suffered 
from ILD, which can also be viewed as a limitation since patients with the diffuse disease 
can also suffer from ILD. This study is part of a larger biomarker study that assessed 
biomarkers for other conditions of the disease like skin progression in dSSc patients. 
Thus, in order to avoid any possible confounders between skin progression and ILD only 
lSSc subjects were selected in this study. The ideal validation cohort for the possible 
prognostic biomarkers identified in this study should also include subjects with dSSc in 
order to evaluate whether this findings also apply to this population. This would allow us 
to increase the power of the study and allow us to build better models to determine 
whether other possible confounders such as the use of immunosupresors affect the 
results.  
 For future studies instead of a binary classification of progression, the correlation 
of these markers with FVC as a continuous variable would be interesting. In order to 
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determine if particular levels of the proteins are associated with degree of decrease in 
pulmonary function. In addition, it would be interesting to include other PFT 
measurements such as the diffusing capacity of the lungs for carbon monoxide (DLCO) 
in order to evaluate whether the identified proteins have an effect in this measurement. 
Other studies could evaluate if the extent of fibrosis assessed by HRCT correlate with the 
proteins, which was not possible in this study due to the lack of this data.  
 This study is the first of its kind to use a high throughput technology to 
investigate the proteome of SSc and show large numbers of proteins differentially 
regulated between those subjects with and without progressive ILD. In particular 
combining the levels in the concentration of Calpain-1 and Coagulation Factor V in the 
serum of subjects with progressive ILD allowed for the best prediction of clinical 
deterioration. These findings could also help understand more of the not completely 
understood pathogenesis of the disease and provides other possible targets for new 
therapeutic options. Validation of these markers utilizing commonly used diagnostic tools 
such as enzyme-linked immunosorbent assay (ELISA) will be important to determine if 
these analytes can be evaluated using more cost-effective technology that will be 
practical for use in the clinical setting. In order to validate these potential prognostic 
biomarkers in the clinical setting, studies with a larger number of subjects will be needed 
to confirm their reproducibility. However, we provide early evidence of the prognostic 
ability of these markers to identify those subjects with progressive ILD from those with 
stable ILD. The validation of these analytes could potentially impact the way clinicians 
decide the course of treatment for patients with progressive ILD by allowing them to 
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provide early treatment in order to minimize or prevent further disease progression. In 
addition, clinical trials could benefit from the validation of these markers. These 
prognostic markers would allow the recruitment of those subjects who suffer from 
progressive disease thus enriching trials with the target population and minimizing the 
risk of including subjects with stable disease. The validation of these novel proteins can 
also help fathom the not fully understood pathogenesis of the disease and provide 
alternative therapeutic targets for drug or biologic development. 
 In this study we provided early evidence of the prognostic ability of Calpain-1 
and Coagulation Factor V to identify those patients with progressive ILD from those with 
stable ILD.  
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